(Q36121068)

12 August 2017

1 reference

title

The immune system, amyloid-beta peptide, and Alzheimer's disease (English)

1 reference

12 August 2017

0 references

2

Gunnar Gouras

1 reference

12 August 2017

Marc E Weksler

1

1 reference

PubMed ID

15882358

12 August 2017

Norman R Relkin

series ordinal

3

1 reference

PubMed ID

15882358

12 August 2017

Paul Szabo

series ordinal

4

1 reference

12 August 2017

1 June 2005

1 reference

12 August 2017

Immunological Reviews

1 reference

12 August 2017

205

1 reference

12 August 2017

244-256

1 reference

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Reciprocal change with age in antibody to extrinsic and intrinsic antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

The effect of age on B cell development and humoral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Neuroimmunology of the paraneoplastic neurological degenerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Do age-associated changes in 'physiologic' autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Toward Alzheimer therapies based on genetic knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Intraneuronal Abeta42 accumulation in human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Abeta42, presenilins, and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Autoantibodies to amyloid-beta and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

Immunotherapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2005.00264.X

10.1111/J.0105-2896.2005.00264.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15882358